Cargando…

Cholera Toxin Enhances Vaccine-Induced Protection against Mycobacterium Tuberculosis Challenge in Mice

Interleukin (IL)-17 is emerging as an important cytokine in vaccine-induced protection against tuberculosis disease in animal models. Here we show that compared to parenteral delivery, BCG delivered mucosally enhances cytokine production, including interferon gamma and IL-17, in the lungs. Furthermo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griffiths, Kristin L., Stylianou, Elena, Poyntz, Hazel C., Betts, Gareth J., Fletcher, Helen A., McShane, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806838/ https://www.ncbi.nlm.nih.gov/pubmed/24194918 http://dx.doi.org/10.1371/journal.pone.0078312

Ejemplares similares

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis()
por: Poyntz, Hazel C., et al.
Publicado: (2014)

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
por: Betts, Gareth, et al.
Publicado: (2012)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
por: Stylianou, Elena, et al.
Publicado: (2019)

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy
por: Minassian, Angela M., et al.
Publicado: (2011)

A New Vaccine for Tuberculosis: The Challenges of Development and Deployment
por: Fletcher, Helen A., et al.
Publicado: (2009)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
por: Stylianou, E., et al.
Publicado: (2015)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges
por: Morrison, Hazel, et al.
Publicado: (2023)

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge
por: Stylianou, Elena, et al.
Publicado: (2023)

A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin
por: Minassian, Angela M., et al.
Publicado: (2012)

Local Pulmonary Immunological Biomarkers in Tuberculosis
por: Morrison, Hazel, et al.
Publicado: (2021)

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A
por: Griffiths, Kristin L., et al.
Publicado: (2011)

Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
por: Dockrell, Hazel M., et al.
Publicado: (2022)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2016)

Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine
por: Stylianou, Elena, et al.
Publicado: (2018)

Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge
por: Monin, Leticia, et al.
Publicado: (2015)

Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A
por: Matsumiya, Magali, et al.
Publicado: (2013)

Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
por: Pinpathomrat, Nawamin, et al.
Publicado: (2021)

Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis
por: Smith, Steven G., et al.
Publicado: (2009)

Tuberculosis vaccines: beyond bacille Calmette–Guérin
por: McShane, Helen
Publicado: (2011)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: McShane, Helen, et al.
Publicado: (2016)

Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis?
por: McShane, Helen
Publicado: (2020)

Improving Tuberculosis Vaccine Trial Efficiency: A Tough Nut to Crack
por: McShane, Helen
Publicado: (2023)

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
por: Satti, Iman, et al.
Publicado: (2022)

Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining
por: Smith, Steven G, et al.
Publicado: (2010)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
por: Villarreal-Ramos, Bernardo, et al.
Publicado: (2014)

Why don’t we have an effective tuberculosis vaccine yet?
por: Davenne, Tamara, et al.
Publicado: (2016)

The next 10 years for tuberculosis vaccines: do we have the right plans in place?
por: Meyer, Joel, et al.
Publicado: (2013)

Toxin secretion and trafficking by Mycobacterium tuberculosis
por: Pajuelo, David, et al.
Publicado: (2021)

Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations
por: Hanekom, Willem A, et al.
Publicado: (2008)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation
por: Sibley, Laura, et al.
Publicado: (2021)

Inhibition of Cholera Toxin and Other AB Toxins by Polyphenolic Compounds
por: Cherubin, Patrick, et al.
Publicado: (2016)

Progress and challenges in TB vaccine development
por: Voss, Gerald, et al.
Publicado: (2018)

Identification of antigens presented by MHC for vaccines against tuberculosis
por: Bettencourt, Paulo, et al.
Publicado: (2020)

Multiple Toxin-Antitoxin Systems in Mycobacterium tuberculosis
por: Sala, Ambre, et al.
Publicado: (2014)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
por: O’Shea, Matthew K., et al.
Publicado: (2018)

A novel recombinant DNA vaccine encoding Mycobacterium tuberculosis ESAT-6 and FL protects against Mycobacterium tuberculosis challenge in mice
por: Jiang, Qingtao, et al.
Publicado: (2013)

Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis
por: Hopkins, Richard, et al.
Publicado: (2011)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9gun1h77tjbvvo7io6kdhmorsl